Intrathecal rituximab for IgG4-related hypertrophic pachymeningitis

Volume: 89, Issue: 4, Pages: 441 - 444
Published: Aug 17, 2017
Abstract
Intrathecal administration of rituximab—an anti-CD20 monoclonal antibody—is emerging as a promising therapeutic strategy for B cell lymphomas of the central nervous system (CNS).1 2 The rationale for administering rituximab directly into the cerebrospinal fluid (CSF) stems from the need to achieve optimal therapeutic concentrations within the intrathecal compartment. Rituximab, in fact, has a high molecular weight and only 0.1%–0.5% of its...
Paper Details
Title
Intrathecal rituximab for IgG4-related hypertrophic pachymeningitis
Published Date
Aug 17, 2017
Volume
89
Issue
4
Pages
441 - 444
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.